Treating hereditary chronic emphysema

Israeli biotech Kamada received patent approval for its unique protein proprietary technologies used to produce the company’s intravenous AAT drug. GLASSIA treats chronic emphysema due to congenital deficiency of AAT (Alpha-1 Antitrypsin), an under-diagnosed hereditary condition, which causes irreversible damage to lung tissue, severe lung disease, and even death.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.